Smith-Lemli-Opitz syndrome

Smith-Lemli-Opitz syndrome is a developmental disorder that affects many parts of the body. This condition is characterized by distinctive facial features, small head size (microcephaly), intellectual disability or learning problems, and behavioral problems. Many affected children have the characteristic features of autism, a developmental condition that affects communication and social interaction. Malformations of the heart, lungs, kidneys, gastrointestinal tract, and genitalia are also common. Infants with Smith-Lemli-Opitz syndrome have weak muscle tone (hypotonia), experience feeding difficulties, and tend to grow more slowly than other infants. Most affected individuals have fused second and third toes (syndactyly), and some have extra fingers or toes (polydactyly).

The signs and symptoms of Smith-Lemli-Opitz syndrome vary widely. Mildly affected individuals may have only minor physical abnormalities with learning and behavioral problems. Severe cases can be life-threatening and involve profound intellectual disability and major physical abnormalities.

Frequency

Smith-Lemli-Opitz syndrome affects an estimated 1 in 20,000 to 60,000 newborns. This condition is most common in whites of European ancestry, particularly people from Central European countries such as Slovakia and the Czech Republic. It is very rare among African and Asian populations.

Causes

Smith-Lemli-Opitz syndrome is caused by mutations in the DHCR7 gene, which provides instructions for making an enzyme called 7-dehydrocholesterol reductase. This enzyme is responsible for the final step in the production of cholesterol. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). Cholesterol is necessary for normal embryonic development and has important functions both before and after birth. It is a structural component of cell membranes and the protective substance covering nerve cells (myelin). Additionally, cholesterol plays a role in the production of certain hormones and digestive acids.

Mutations in the DHCR7 gene reduce or eliminate the activity of 7-dehydrocholesterol reductase, preventing cells from producing enough cholesterol. A lack of this enzyme also allows toxic byproducts of cholesterol production to build up in the blood, nervous system, and other tissues. The combination of low cholesterol levels and an accumulation of other substances likely disrupts the growth and development of many
body systems. It is not completely understood, however, how either abnormality leads to the specific features of Smith-Lemli-Opitz syndrome.

Inheritance Pattern
This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition
• 7-dehydrocholesterol reductase deficiency
• RSH Syndrome
• SLO syndrome
• SLOS

Diagnosis & Management
Genetic Testing Information
• What is genetic testing?
   /primer/testing/genetictesting
• Genetic Testing Registry: Smith-Lemli-Opitz syndrome

Research Studies from ClinicalTrials.gov
• ClinicalTrials.gov
   https://clinicaltrials.gov/ct2/results?cond=%22smith-lemli-opitz+syndrome%22

Other Diagnosis and Management Resources
• GeneReview: Smith-Lemli-Opitz Syndrome
   https://www.ncbi.nlm.nih.gov/books/NBK1143

Additional Information & Resources
Health Information from MedlinePlus
• Health Topic: Developmental Disabilities
   https://medlineplus.gov/developmentaldisabilities.html
• Health Topic: Lipid Metabolism Disorders
   https://medlineplus.gov/lipidmetabolismdisorders.html

Genetic and Rare Diseases Information Center
• Smith-Lemli-Opitz syndrome
Educational Resources

• Genetic Science Learning Center, University of Utah
  https://learn.genetics.utah.edu/content/disorders/singlegene/

• Kennedy Krieger Institute

• MalaCards: smith-lemli-opitz syndrome
  https://www.malacards.org/card/smith_lemli_opitz_syndrome

• Orphanet: Smith-Lemli-Opitz syndrome
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=818

Patient Support and Advocacy Resources

• National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/smith-lemli-opitz-syndrome/

• Resource list from the University of Kansas Medical Center
  http://www.kumc.edu/gec/support/smith-le.html

• Smith-Lemli-Opitz/RSH Foundation
  https://www.smithlemliopitz.org/

Clinical Information from GeneReviews

• Smith-Lemli-Opitz Syndrome
  https://www.ncbi.nlm.nih.gov/books/NBK1143

Scientific Articles on PubMed

• PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Smith-Lemli-Opitz+Syndrome%5BMAJR%5D%29+AND+%28Smith-Lemli-Opitz+syndrome%5BTIAB%5D%29+AND+english%5BLa%5D+AND+human%5Bmh%5D+AND+%22last+1080+days%22%5Bdp%5D

Catalog of Genes and Diseases from OMIM

• SMITH-LEMLI-OPITZ SYNDROME
  http://omim.org/entry/270400

Sources for This Summary

Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4343216/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16906538

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11453964

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301322

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11001807

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16761297

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23042628

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16207203
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1350989/

Reprinted from Genetics Home Reference: 

Reviewed: January 2020
Published: August 17, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services